Treatment perspectives in advanced non-small cell lung cancer

Tumori

Volumn 86, Issue 5 SUPPL. 1, 2000, Pages

  Soto Parra, H ^a   Latteri, F ^a   Cavina, R ^a   Sala, A ^a   Dambrosio, M ^a   Alloisio, M ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ERLOTINIB; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TIRAPAZAMINE; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID; VINDESINE;

ADJUVANT CHEMOTHERAPY; ANEMIA; ARTHRALGIA; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DYSESTHESIA; FEVER; GRANULOCYTOPENIA; HEARING LOSS; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NEUROPATHY; NEUTROPENIA; ONCOGENE C ERB; ONCOGENE NEU; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RASH; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FOLIC ACID; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; SIGNAL TRANSDUCTION;

EID: 0034487563     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
2. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
3. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma
4. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
5. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
6. Multitargeted antifolate MTA (LY231514): An active agent in advanced non-small cell lung cancer (NSCLC)
7. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
8. Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small cell lung cancer: A phase II randomized study of the Southern Italy Cooperative Oncology Group
9. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
10. Gemcitabine as second-line treatment for advanced non-small cell lung cancer. A phase II trial
11. Growth factors in the development, trasformation and tumorigenesis
12. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life
13. Preliminary report on oxaliplatin (L-OHP/navelbine (NVB) phase I/II multicentric trial in patients (pts) with advanced non-small celll lung cancer (NSCLC): An active combination
14. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
15. Paclitaxel and carboplatin with gemcitabine (PCG): A phase I-II trial in non-small cell lung cancer (NSCLC)
16. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
17. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas
18. 2 vs vinorelbine/ifosfamide for non-small cell lung cancer previously treated with platinum-based chemotherapy (PBC)
19. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small cell lung cancer. A phase I study
20. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
21. A phase I-II study of gemcitabine and paclitaxel in advanced non-small cell lung cancer patients
22. A phase II of gemcitabine, cisplatin, and vinorelbine in patients with advanced non-small cell lung cancer
23. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
24. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: A phase II study of three different doses
25. Protein kinase C targeting in antineoplastic treatment strategies
26. Phase I dose escalation study of epidermal growth factor recptor (EGFR) tyrosine kinase (TK) inhibitor CP-358.774 in patients with advanced solid tumors
27. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cispaltin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group Trial
28. A phase 1 trial of paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced non-small cell lung cancer: A University of Colorado Cancer Centre study
29. A phase II study of docetaxel, vinorelbine G-CSF chemotherapy in patients ,with unresectable or metastatic non-small cell cancer of the lung
30. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer
31. MTA (Multitargeted Antifolate, LY231514) in NSCLC patients who failed previous platinum or non-platinum chemotherapy: A phase II trial
32. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
33. ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques
34. Matrix metalloproteinases: Biologic activity and clinical implications
35. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials: Non-small Cell Lung Cancer Collaborative Group
36. Phase II trial of taxotere (T) and navelbine (N) as first-line therapy in patients with advanced non-small cell lung cancer
37. Combination chemotherapy with carboplatin docetaxel and gemcitabine in advanced non-small cell lung cancer: A phase II study
38. Oxaliplatin: A review of preclinical and clinical studies
39. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
40. Differential expression of the epidermal growth factors receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
41. Phase III trial of gemcitabine plus cisplatin versus cispaltin alone in patients with locally advanced or metastatic non-small cell lung cancer
42. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
43. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs
44. Phase I and pharmacokinetic study of tirapazamine (SR4233) administered every three weeks
45. Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer patients previously treated with platinum-based chemotherapy
46. Phase II study of MTA (Alimta) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC)
47. Addition of herceptin (humanized anti-her2 antibody) to firts line chemotherapy for her2 overexpressing metastatic breast cancer (her2+/mbc) markedly increases anticancer activity: A randomized multinational controlled phase II trial
48. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small cell lung tumors
49. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
50. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
51. Biweekly docetaxel (DOC), gemcitabine (GEM) and oxaliplatin (LOHP) in pretreated patients with solid tumors. Results of a phase I study
52. Similarity of protein encoded by human c-erb-B-2 gene to epidermal growth factor receptor
53. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonist to the receptors of vascular endothelial growth factor